GERIATRIC CAR-T CELLS AND USES THEREOF
Chimeric antigen receptors (CARs) expressing T cells are a promising form of immunotherapy for solid tumors. CAR-T cells from geriatric donors (gCART) are shown herein to be functionally impaired relative to CAR-T from younger donors (yCAR-T). Higher transduction efficiencies and improved cell expansion were observed in yCAR-T cells compared to gCAR-T. yCAR-T demonstrated significantly increased levels of proliferation and signaling activation of pERK, pAKT, pSTAT3 and pSTAT5. Furthermore, yCAR-T contained higher proportions of CD4 and CD8 effector memory cells (EM) which are known to have enhanced cytolytic capabilities. In accordance with higher numbers of CD4 and CD8 EM, yCAR-T demonstrated higher levels of CEA specific cytotoxicity compared to gCAR-T, with maximum cytotoxicity observed in IL15 treated yCAR-T cells.
1 . A method for transducing a population of lymphocytes ex vivo, comprising
contacting ex vivo the lymphocytes with an agent which increases expression of α5β1 by the lymphocytes; and
mixing the lymphocytes with a recombinant viral particle which comprises a recombinant DNA molecule encoding a chimeric antigen receptor (CAR).
2 . The method according to claim 1 , wherein the contacting the lymphocytes with the agent comprises incubating the lymphocytes with the agent.
3 . The method according to claim 1 , wherein the agent comprises M-CSF or TGβ1.
4 . The method according to claim 1 , wherein the contacting the lymphocytes with the agent comprises incubating the lymphocytes with 0.1 ng/ml to 10 ng/ml, 2.5 ng/ml to 7.5 ng/ml or 4 ng/ml to 7 ng/ml M-CSF.
5 . The method according to claim 1 , wherein the contacting the cells with the agent comprises incubating the cells with 1 ng/ml to 20 ng/ml, 5 ng/ml to 15 nm/ml, or 7.5 ng/ml to 12.5 ng/ml TG931.
6 . The method of claim 1 , wherein prior to contacting the cells with the agent the cells are obtained from a subject diagnosed with a disease.
7 . The method of claim 6 , wherein the disease is a cancer or an acquired immunodeficiency disease.
8 . The method of claim 7 , wherein the cancer is selected from the group consisting of a liver cancer, a pancreatic cancer, a leukemia, a lymphatic cancer, a brain cancer, a head & neck cancer, a lung cancer, a breast cancer, a thyroid cancer, a prostate cancer, a stomach cancer, an esophageal cancer, a colon cancer, a rectal cancer, a testicular cancer, a bladder cancer, a cervical cancer, an ovarian cancer and a skin cancer.
9 . The method of claim 8 , wherein the disease is a cancer or an acquired immunodeficiency disease.
10 . The method of claim 1 , wherein the recombinant viral particle is a lentiviral, retroviral, adenoviral or adeno-associated viral vector.
11 . A method for treating a subject in need thereof comprising administering to the subject a composition comprising a CAR-T generated using the method according to claim 1 .
12 . The method according to claim 11 , wherein the subject is at least 65 years old.